Exploiting dendritic cells for active immunotherapy of cancer and chronic infections

Molecular Biotechnology

Volumn 36, Issue 2, 2007, Pages 131-141

  O'Neill, David W ^a   Bhardwaj, Nina ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presenting; Cancer; Dendritic; Vaccine

Indexed keywords

CELLS; IMMUNOLOGY; ONCOLOGY; VACCINES;

ANTIGEN PRESENTING; CANCER; DENDRITIC;

DENDRIMERS;

ANTIGEN; DNA; RNA; CANCER VACCINE; VACCINE;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; APOPTOSIS; CANCER; CELL LYSATE; CELL MATURATION; CELL TYPE; DENDRITIC CELL; EX VIVO STUDY; HUMAN; IMMUNOTHERAPY; INFECTION; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NONHUMAN; REVIEW; ACTIVE IMMUNIZATION; CHRONIC DISEASE; IMMUNOLOGY; METHODOLOGY; NEOPLASM;

ANTIGEN PRESENTATION; CANCER VACCINES; CHRONIC DISEASE; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; INFECTION; NEOPLASMS; VACCINES;

EID: 35848929035     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-007-0020-6     Document Type: Review

References (153)

1. Palucka, K., & Banchereau, J. (1999). Linking innate and adaptive immunity. Nature Medicine, 5, 868-870.
2. Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006). Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Advances in Immunology, 90, 1-50.
3. Sant, A., & Yewdell, J. (2003). Antigen processing and recognition. Current Opinion in Immunology, 15, 66-68.
4. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., & Palucka, K. (2000). Immunobiology of dendritic cells. Annual Review of Immunology, 18, 767-811.
5. Ardavin, C., Amigorena, S., & Reis e Sousa, C. (2004). Dendritic cells: immunobiology and cancer immunotherapy. Immunity, 20, 17-23.
6. Bhardwaj, N., Friedman, S. M., Cole, B. C., & Nisanian, A. J. (1992). Dendritic cells are potent antigen-presenting cells for microbial superantigens. The Journal of Experimental Medicine, 175, 267-273.
7. Fonteneau, J. F., Larsson, M., Somersan, S., Sanders, C., Munz, C., Kwok, W. W., Bhardwaj, N., & Jotereau, F. (2001). Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. Journal of Immunological Methods, 258, 111-126.
8. Steinman, R. M., & Pope, M. (2002). Exploiting dendritic cells to improve vaccine efficacy. The Journal of Clinical Investigation, 109, 1519-1526.
9. Shortman, K., & Liu, Y. J. (2002). Mouse and human dendritic cell subtypes. Nature Reviews. Immunology, 2, 151-161.
10. MacDonald, K. P., Munster, D. J., Clark, G. J., Dzionek, A., Schmitz, J., & Hart, D. N. (2002). Characterization of human blood dendritic cell subsets. Blood, 15, 15.
11. Clark, G., Munster, D., Yusuf, S., & Hart, D. N. (2005). Eighth leucocyte differentiation antigen workshop DC section summary. Cellular Immunology, 236, 21-28.
12. O'Keeffe, M., Hochrein, H., Vremec, D., Scott, B., Hertzog, P., Tatarczuch, L., & Shortman, K. (2003). Dendritic cell precursor populations of mouse blood: Identification of the murine homologues of human blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. Blood, 101, 1453-1459.
13. Soumelis, V., & Liu,Y. J. (2006). From plasmacytoid to dendritic cell: Morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. European Journal of Immunology, 36, 2286-2292.
14. Zenke, M., & Hieronymus, T. (2006). Towards an understanding of the transcription factor network of dendritic cell development. Trends in Immunology, 27, 140-145.
15. Manz, M. G., Traver, D., Miyamoto, T., Weissman, I. L., & Akashi, K. (2001). Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood, 97, 3333-3341.
16. Wu, L., D'Amico, A., Hochrein, H., O'Keeffe, M., Shortman, K., & Lucas, K. (2001). Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood, 98, 3376-3382.
17. D'Amico, A., & Wu, L. (2003). The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. The Journal of Experimental Medicine, 198, 293-303.
18. del Hoyo, G. M., Martin, P., Vargas, H. H., Ruiz, S., Arias C. F., & Ardavin, C. (2002). Characterization of a common precursor population for dendritic cells. Nature, 415, 1043-1047.
19. Peiser, L., Mukhopadhyay, S., & Gordon, S. (2002). Scavenger receptors in innate immunity. Current Opinion in Immunology, 14, 123-128.
20. Rafiq, K., Bergtold, A., & Clynes, R. (2002). Immune complex-mediated antigen presentation induces tumor immunity. The Journal of Clinical Investigation, 110, 71-79.
21. Schuurhuis, D. H., Ioan-Facsinay, A., Nagelkerken, B., van Schip, J. J., Sedlik, C., Melief, C. J., Verbeek, J. S., & Ossendorp, F. (2002). Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. Journal of Immunology, 168, 2240-2246.
22. Figdor, C. G., van Kooyk, Y., & Adema, G. J. (2002). C-type lectin receptors on dendritic cells and Langerhans cells. Nature Reviews. Immunology, 2, 77-84.
23. Aarnoudse, C. A., Garcia Vallejo, J. J., Saeland, E., & van Kooyk, Y. (2006). Recognition of tumor glycans by antigen-presenting cells. Current Opinion in Immunology, 18, 105-111.
24. Steinman, R. M., & Nussenzweig, M. C. (2002). Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proceedings of the National Academy of Sciences of the United States of America, 99, 351-358.
25. Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003). Tolerogenic dendritic cells. Annual Review of Immunology, 21, 685-711.
26. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., & Nussenzweig, M. C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. The Journal of Experimental Medicine, 194, 769-779.
27. Aderem, A., Ulevitch RJ (2000). Toll-like receptors in the induction of the innate immune response. Nature, 406, 782-787.
28. Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nature Reviews. Immunology, 1, 135-145.
29. Gallucci, S., & Matzinger, P. (2001). Danger signals: SOS to the immune system. Current Opinion in Immunology, 13, 114-119.
30. Pulendran, B., Palucka, K., & Banchereau, J. (2001). Sensing pathogens and tuning immune responses. Science, 293, 253-256.
31. Takeda, K., Kaisho, T., & Akira, A. (2003). Toll-like receptors. Annual Review of Immunology, 21, 335-376.
32. Shi, Y., Evans, J. E., & Rock, K. L. (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 425, 516-521.
33. Mellman, I., & Steinman, R. M. (2001). Dendritic cells: Specialized and regulated antigen processing machines. Cell, 106, 255-258.
34. Kloetzel, P. M., & Ossendorp, F. (2004). Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Current Opinion in Immunology, 16, 76-81.
35. Lanzavecchia, A., & Sallusto, F. (2001). The instructive role of dendritic cells on T cell responses: Lineages, plasticity and kinetics. Current Opinion in Immunology, 13, 291-289.
36. Moody, D. B., & Porcelli, S. A. (2002). Intracellular pathways of CD1 antigen presentation. Nature Reviews. Immunology, 3, 11-22.
37. Porcelli, S. A., & Modlin, R. L. (1999). The CD1 system: antigen presenting molecules for T cell recognition of lipids and glycolipids. Annual Review of Immunology, 17, 297-329.
38. Fujii, S., Shimizu, K., Kronenberg, M., & Steinman, R. M. (2002). Prolonged IFN-gamma-producing NKT response induced with alpha- galactosylceramide-loaded DCs. Nature Immunology, 3, 867-874.
39. Kronenberg, M., & Gapin, L. (2002). The unconventional lifestyle of NKT cells. Nature Reviews. Immunology, 2, 7-568.
40. Bhardwaj, N. (2001). Processing and presentation of antigens by dendritic cells: Implications for vaccines. Trends in Molecular Medicine, 7, 388-394.
41. Heath, W. R., & Carbone, F. R. (2001). Cross-presentation in viral immunity and self-tolerance. Nature Reviews. Immunology, 1, 126-134.
42. Rock, K. L., & Shen, L. (2005). Cross-presentation: Underlying mechanisms and role in immune surveillance. Immunological Reviews, 207, 166-183.
43. Bevan, M. J. (2006). Cross-priming. Nature Immunology, 7, 363-365.
44. Kalergis, A. M., & Ravetch, J. V. (2002). Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. The Journal of Experimental Medicine, 195, 1653-1659.
45. Savill, J., Dransfield, I., Gregory, C., & Haslett, C. (2002). A blast from the past: clearance of apoptotic cells regulates immune responses. Nature Reviews. Immunology, 2, 965-975.
46. Schulz, O., Diebold, S. S., Chen, M., Naslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y. T., Flavell, R. A., & Liljestrom, P. (2005). Reis e Sousa C: Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature, 433, 887-892.
47. Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D., Borrow, P., & Tough, D. F. (2003). Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nature Immunology, 4, 1009-1015.
48. Lapenta, C., Santini, S. M., Spada, M., Donati, S., Urbani, F., Accapezzato, D., Franceschini, D., Andreotti, M., Barnaba, V., & Belardelli, F. (2006). IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. European Journal of Immunology, 36, 2046-2060.
49. Stoll, S., Delon, J., Brotz, T. M., & Germain, R. N. (2002). Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science, 296, 1873-1876.
50. Norbury, C. C., Malide, D., Gibbs, J. S., Bennink, J. R., & Yewdell, J. W. (2002). Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nature Immunology, 3, 265-271.
51. Langenkamp, A., Casorati, G., Garavaglia, C., Dellabona, P., Lanzavecchia, A., & Sallusto, F. (2002). T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. European Journal of Immunology, 32, 2046-2054.
52. Gett, A. V., Sallusto, F., Lanzavecchia, A., & Geginat, J. (2003). T cell fitness determined by signal strength. Nature Immunology, 4, 355-360.
53. Palucka, K., & Banchereau, J. (2002). How dendritic cells and microbes interact to elicit or subvert protective immune responses. Current Opinion in Immunology, 14, 420-431.
54. Boonstra, A., Asselin-Paturel, C., Gilliet, M., Crain, C., Trinchieri, G., & Liu, Y. J., O'Garra A. (2003). Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. The Journal of Experimental Medicine, 197, 101-109.
55. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., & Lanzavecchia, A. (2005). Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunology, 6, 769-776.
56. Lanzavecchia, A., & Sallusto, F. (2005). Understanding the generation and function of memory T cell subsets. Current Opinion in Immunology, 17, 326-332.
57. Lutz, M., & Schuler, G. (2002). Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends in Immunology, 23, 445.
58. Kaech, S. M., & Ahmed, R. (2003). CD8 T cells remember with a little help. Science, 300, 263-265.
59. Ahmed, R., & Rouse, B. T. (2006). Immunological memory. Immunological Reviews, 211, 5-7.
60. Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews. Immunology, 3, 133-146.
61. Balazs, M., Martin, F., Zhou, T., & Kearney, J. (2002). Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity, 17, 341-352.
62. Jego, G., Palucka, A. K., Blanck, J. P., Chalouni, C., Pascual, V., & Banchereau, J. (2003). Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity, 19, 225-234.
63. Ferlazzo, G., Tsang, M. L., Moretta, L., Melioli, G., Steinman, R. M., & Munz, C. (2002). Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. The Journal of Experimental Medicine, 195, 343-351.
64. Berzofsky, J. A., Ahlers, J. D., & Belyakov, I. M. (2001). Strategies for designing and optimizing new generation vaccines. Nature Reviews. Immunology, 1, 209-219.
65. Berzofsky, J. A., Ahlers, J. D., Janik, J., Morris, J., Oh S., Terabe M., & Belyakov, I. M. (2004). Progress on new vaccine strategies against chronic viral infections. The Journal of Clinical Investigation, 114, 450-462.
66. Pal, R., Venzon, D., Santra, S., Kalyanaraman, V. S., Montefiori, D. C., Hocker, L., Hudacik, L., Rose, N., Nacsa, J., Edghill-Smith, Y., et al. (2006). Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. Journal of Virology, 80, 3732-3742.
67. Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., & Old, L. J., & Schreiber, R. D. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107-1111.
68. Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001). A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology, 2, 293-299.
69. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 3, 991-998.
70. Boon, T., & Old, L. J. (1997). Cancer Tumor antigens. Current Opinion in Immunology, 9, 681-683.
71. Houghton, A. N., Gold, J. S., & Blachere, N. E. (2001). Immunity against cancer: lessons learned from melanoma. Current Opinion in Immunology, 13, 134-140.
72. Stevanovic, S. (2002). Identification of tumour-associated T-cell epitopes for vaccine development. Nature Reviews. Cancer, 2, 514-520.
73. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., et al. (1999). Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine, 5, 1171-1177.
74. Livingston, P. (2001). The unfulfilled promise of melanoma vaccines. Clinical Cancer Research, 7, 1837-1838.
75. Nestle, F. O. (2002). Vaccines and melanoma. Clinical and Experimental Dermatology, 27, 597-601.
76. Machiels, J. P., van Baren, N., & Marchand, M. (2002). Peptide-based cancer vaccines. Seminars in Oncology, 29, 494-502.
77. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999). Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA- A1. International Journal of Cancer, 80, 219-230.
78. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 4, 321-327.
79. Sabel, M. S., & Sondak, V. K. (2002). Tumor vaccines: a role in preventing recurrence in melanoma? American Journal of Clinical Dermatology, 3, 609-616.
80. McClay, E. F. (2002). Adjuvant therapy for patients with high-risk malignant melanoma. Seminars in Oncology, 29, 389-399.
81. Banchereau, J., Schuler-Thurner, B., Palucka, A. K., & Schuler, G. (2001). Dendritic cells as vectors for therapy. Cell, 106, 271-274.
82. Banchereau, J., & Palucka, A. K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nature Reviews. Immunology, 5, 296-306.
83. Ashley, D. M., Faiola, B., Nair, S., Hale, L. P., Bigner, D. D., & Gilboa, E. (1997). Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. The Journal of Experimental Medicine, 186, 1177-1182.
84. Celluzzi, C. M., & Falo, L. D. Jr. (1998). Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. Journal of Immunology, 160, 3081-3085.
85. Gilboa, E., Nair, S. K., & Lyerly, H. K. (1998). Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother, 46, 82-87.
86. Porgador, A., Snyder, D., & Gilboa, E. (1996). Induction of antitumor immunity using bone marrow-generated dendritic cells. Journal of Immunology, 156, 2918-2926.
87. Dhodapkar, M. V., Steinman, R. M., Sapp, M., Desai, H., Fossella, C., Krasovsky, J., Donahoe, S. M., Dunbar, P. R., Cerundolo, V., Nixon, D. F., et al. (1999). Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. The Journal of Clinical Investigation, 104, 173-180.
88. Dhodapkar, M. V., Krasovsky, J., Steinman, R. M., & Bhardwaj, N. (2000). Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. The Journal of Clinical Investigation, 105, R9-R14.
89. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Research, 61, 6451-6458.
90. Schuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N., et al. (2002). Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide- loaded monocyte-derived dendritic cells. The Journal of Experimental Medicine, 195, 1279-1288.
91. Tuettenberg, A., Becker, C., Huter, E., Knop, J., Enk, A. H., & Jonuleit, H. (2006). Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. International Journal of Cancer, 118, 2617-2627.
92. Palucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J. P., Johnston, D. A., Fay, J., & Banchereau, J. (2006). Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Journal of Immunotherapy, 29, 545-557.
93. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C. A., Becker, V., et al. (2000). Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Medicine, 6, 332-336.
94. Wierecky, J., Muller, M. R., Wirths, S., Halder-Oehler, E., Dorfel, D., Schmidt, S. M., Hantschel, M., Brugger, W., Schroder, S., Horger, M. S., et al. (2006). Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Research, 66, 5910-5918.
95. Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., et al. (2002). Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 99, 1517-1526.
96. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nature Medicine, 2, 52-58.
97. Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002). Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. The Journal of Clinical Investigation, 109, 409-417.
98. Fong, L., Brockstedt, D., Benike, C., Wu, L., & Engleman, E. G. (2001). Dendritic cells injected via different routes induce immunity in cancer patients. Journal of Immunology, 166, 4254-4259.
99. Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L., & Engleman, E. G. (2001). Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. Journal of Immunology, 167, 7150-7156.
100. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., & Valone, F. H. (2000). Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. Journal of Clinical Oncology, 18, 3894-3903.
101. Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R. L., Padley, D. J., Peshwa, M. V., Pitot, H. C., Richardson, R. L., et al. (2000). Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clinical Cancer Research, 6, 2175-2182.
102. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., & Brugger, W. (2000). Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 96, 3102-3108.
103. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M.M., & Engleman, E. G. (2001). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 98, 8809-8814.
104. Brower, V. (2005). Cancer vaccine field gets shot of optimism from positive results. Nature Medicine, 11, 360.
105. Srivastava, P. K. (2006). Therapeutic cancer vaccines. Current Opinion in Immunology, 18, 201-205.
106. Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., & Enk, A. H. (1997). Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. European Journal of Immunology, 27, 3135-3142.
107. Caux, C., Massacrier, C., Dezutter-Dambuyant, C., Vanbervliet, B., Jacquet, C., Schmitt, D., & Banchereau, J. (1995). Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. Journal of Immunology, 155, 5427-5435.
108. Caux, C., Dezutter-Dambuyant, C., Schmitt, D., & Banchereau, J. (1992). GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature, 360, 258-261.
109. So-Rosillo R., & Small, E. J. (2006). Sipuleucel-T (APC8015) for prostate cancer. Expert Review of Anticancer Therapy, 6, 1163-1167.
110. Mortarini, R., Anichini, A., Di Nicola, M., Siena, S., Bregni, M., Belli, F., Molla, A., Gianni, A. M., & Parmiani, G. (1997). Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)- specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Research, 57, 5534-5541.
111. Jonuleit, H., Giesecke-Tuettenberg, A., Tuting, T., Thurner-Schuler, B., Stuge, T. B., Paragnik, L., Kandemir, A., Lee, P. P., Schuler, G., Knop, J., et al. (2001). A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. International Journal of Cancer, 93, 243-251.
112. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. The Journal of Experimental Medicine, 193, 233-238.
113. Bender, A., Sapp, M., Schuler, G., Steinman, R. M., & Bhardwaj, N. (1996). Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. Journal of Immunological Methods, 196, 121-135.
114. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D., & Schuler, G. (1996). Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. Journal of Immunological Methods, 196, 137-151.
115. Thurner, B., Roder, C., Dieckmann, D., Heuer, M., Kruse, M., Glaser, A., Keikavoussi, P., Kampgen, E., Bender, A., & Schuler, G. (1999). Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. Journal of Immunological Methods, 223, 1-15.
116. Lee, A. W., Truong, T., Bickham, K., Fonteneau, J. F., Larsson, M., Da Silva, I., Somersan, S., Thomas, E. K., & Bhardwaj, N. (2002). A clinical grade cocktail of cytokines and PGE(2) results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine, 20 (Suppl 4), A8-A22.
117. Scandella, E., Men, Y., Gillessen, S., Forster, R., & Groettrup, M. (2002). Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 100, 1354-1361.
118. Alexander-Miller, M. A., Leggatt, G. R., & Berzofsky, J. A. (1996). Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 93, 4102-4107.
119. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine, 4, 328-332.
120. Geiger, J., Hutchinson, R., Hohenkirk, L., McKenna, E., Chang, A., & Mule, J. (2000). Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet, 356, 1163-1165.
121. Chang, A. E., Redman, B. G., Whitfield, J. R., Nickoloff, B. J., Braun, T. M., Lee, P. P., Geiger, J .D., & Mule, J. J. (2002). A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clinical Cancer Research, 8, 1021-1032.
122. Kim, D. T., Mitchell, D. J., Brockstedt, D. G., Fong, L., Nolan, G. P., Fathman, C. G., Engleman, E. G., & Rothbard, J. B. (1997). Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. Journal of Immunology, 159, 1666-1668.
123. Holtl, L., Zelle-Rieser, C., Gander, H., Papesh, C., Ramoner, R., Bartsch, G., Rogatsch, H., Barsoum, A. L., Coggin, J. H. Jr., & Thurnher, M. (2002). Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clinical Cancer Research, 8, 3369-3376.
124. Binder, R. J., & Srivastava, P. K. (2005). Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nature Immunology, 6, 593-599.
125. Tuting, T., Wilson, C. C., Martin, D. M., Kasamon, Y. L., Rowles, J., Ma, D. I., Slingluff, C. L. Jr., Wagner, S. N., van der Bruggen, P., Baar, J., et al. (1998). Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1- biasing cytokines IL-12 and IFN-alpha. Journal of Immunology, 160, 1139-1147.
126. Yang, S., Vervaert, C. E., Burch, J. Jr., Grichnik, J., Seigler, H. F., & Darrow, T. L. (1999). Murine dendritic cells transfected with human GP100 elicit both antigen- specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. International Journal of Cancer, 83, 532-540.
127. Nair, S. K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J. S., Vieweg, J., & Gilboa, E. (2000). Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Medicine, 6, 1011-1017.
128. Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005). Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. Journal of Immunology, 174, 3798-3807.
129. Jenne, L., Schuler, G., & Steinkasserer, A. (2001). Viral vectors for dendritic cell-based immunotherapy. Trends in Immunology, 22, 102-107.
130. Dietz, A. B., & Vuk-Pavlovic, S. (1998). High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood, 91, 392-398.
131. Chaux, P., Luiten, R., Demotte, N., Vantomme, V., Stroobant, V., Traversari, C., Russo, V., Schultz, E., Cornelis, G. R., Boon, T., et al. (1999). Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. Journal of Immunology, 163, 2928-2936.
132. Larsson, M., Fonteneau, J. F., Somersan, S., Sanders, C., Bickham, K., Thomas, E. K., Mahnke, K., & Bhardwaj, N. (2001). Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. European Journal of Immunology, 31, 3432-3442.
133. Engelmayer, J., Larsson, M., Lee, A., Lee, M., Cox, W. I., Steinman, R. M., & Bhardwaj N. (2001). Mature dendritic cells infected with canarypox virus elicit strong anti- human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. Journal of Virology, 75, 2142-2153.
134. Kwak, H., Horig, H., & Kaufman, H. L. (2003). Poxviruses as vectors for cancer immunotherapy. Current Opinion in Drug Discovery & Development, 6, 161-168.
135. Brockstedt, D. G., Bahjat, K. S., Giedlin, M. A., Liu, W., Leong, M., Luckett, W., Gao, Y., Schnupf, P., Kapadia, D., Castro, G., et al. (2005). Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nature Medicine, 11, 853-860.
136. Kotera, Y., Shimizu, K., & Mule, J. J. (2001). Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Research, 61, 8105-8109.
137. Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E. M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D., Cerottini, J. C., Banchereau, J., & Palucka, A. K. (2000). Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. The Journal of Experimental Medicine, 192, 1535-1544.
138. Gong, J., Avigan, D., Chen, D., Wu, Z., Koido, S., Kashiwaba, M., & Kufe, D. (2000). Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 97, 2715-2718.
139. Gong, J., Koido, S., Chen, D., Tanaka, Y., Huang, L., Avigan, D., Anderson, K., Ohno, T., & Kufe, D. (2002). Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 99, 2512-2517.
140. Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., Ricciardi-Castagnoli, P., Raposo, G., & Amigorena, S. (1998). Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Medicine, 4, 594-600.
141. Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., et al. (2001). Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Medicine, 7, 297-303.
142. Schartz, N. E., Chaput, N., Andre, F., & Zitvogel, L. (2002). From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. Current Opinion in Molecular Therapeutics, 4, 372-381.
143. Kerbel, R., & Folkman J. (2002). Clinical translation of angiogenesis inhibitors. Nature Reviews. Cancer, 2, 727-739.
144. Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005). Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. Journal of Clinical Oncology, 23, 8968-8977.
145. Dranoff, G. (2005). CTLA-4 blockade: unveiling immune regulation. Journal of Clinical Oncology, 23, 662-664.
146. Hodi, F. S., & Dranoff, G. (2006). Combinatorial cancer immunotherapy. Advances in Immunology, 90, 341-368.
147. Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006). Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion in Immunology, 18, 206-213.
148. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439, 682-687.
149. Freeman, G. J., Wherry, E. J., Ahmed, R., & Sharpe, A. H. (2006). Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. The Journal of Experimental Medicine, 203, 2223-2227.
150. Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443, 350-354.
151. Homey, B., Muller, A., & Zlotnik, A. (2002). Chemokines: agents for the immunotherapy of cancer? Nature Reviews. Immunology, 2, 175-184.
152. Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A., Sirard, J. C., Rothlisberger, P., & Bachmann, M. F. (2003). Role of Toll-like receptors in costimulating cytotoxic T cell responses. European Journal of Immunology, 33, 1465-1470.
153. Wille-Reece, U., Flynn, B. J., Lore, K., Koup, R. A., Miles, A. P., Saul, A., Kedl, R. M., Mattapallil, J. J., Weiss, W. R., Roederer, M., et al. (2006). Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. The Journal of Experimental Medicine, 203, 1249-1258.